Uro-genital Schistosomiasis
Conditions
Keywords
Uro-genital schistosomiasis, Female, South Africa, Rural, Sexually transmitted diseases
Brief summary
Schistosomiasis is a poverty-related water-transmitted parasitic disease affecting more that 200 million people world wide. Infection with Schistosoma haematobium may cause Female Genital Schistosomiasis (FGS) with pathological lesions in the female genital tract, especially the cervix. Findings indicate that FGS is a hitherto under-diagnosed illness of young women in endemic poor tropical countries, deserving further attention. A cross-sectional study from Zimbabwe indicated that the pathologic genital lesions were unchanged two years after praziquantel treatment in adult women whereas in those who had been treated with praziquantel in childhood the prevalence of genital lesions was significantly lower. Furthermore, a higher prevalence of HIV was detected in women with FGS compared to those without. The proposed project aims at achieving a better understanding of how annual distribution of praziquantel to pre- and post-pubertal schoolgirls may prevent FGS. This information can be of use in current schistosomiasis control programs in the near term resulting in improved strategies for treatment. Preventing or reducing the risk of FGS and genital lesions will lead to improved reproductive health among in women living in schistosomiasis endemic areas. Project Goal: Contribute to a reduction of the global burden of female genital schistosomiasis (FGS) through improved knowledge about the prevention of gynecological lesions and through improved diagnosis of FGS.
Detailed description
Provide a more extensive description, if desired. Avoid duplication of information to be recorded elsewhere, such as eligibility criteria or outcome measures
Interventions
One day, 40mg/kg standard mass Praziquantel as recommended by WHO and local authorities
Sponsors
Study design
Eligibility
Inclusion criteria
* Females in Schistosoma haematobium endemic areas
Exclusion criteria
* Boys * Pregnancy * Allergic to praziquantel * Severe disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| HIV prevalence after anti-schistosomal treatment in adolescents | 31. December 2021 | HIV prevalence |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| FGS prevalence and severity after anti-schistosomal treatment in adolescents | 31. December 2021 | Clinical disease |
| Clinical and laboratory indicators of urogenital schistosomiasis | 31. December 2018 | Polymerase chain reaction (PCR) of vaginal lavage, Cytology, Circulation Anodic Antigen (CAA) |
Other
| Measure | Time frame | Description |
|---|---|---|
| Pocket Atlas of Female Genital Schistosomiasis | 31. December 2015 | Published by WHO in English, French and Portuguese |
Countries
South Africa